研究单位：[1]Sichuan Cancer Hospital and Research Institute[2]Peking University Cancer Hospital & Institute[3]Tianjin Medical University Cancer Institute and Hospital[4]Hebei Medical University Fourth Hospital[5]Anhui Provincial Hospital[6]The First Affiliated Hospital with Nanjing Medical University[7]Anyang Tumor Hospital[8]Shantou Central Hospital[9]Innovent Biologics (Suzhou) Co. Ltd.[10]GeneCast Biotechnology Co.,Ltd.
研究目的：
Tislelizumab Inhibitor Plus Neoadjuvant Chemotherapy Versus Plus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Multicenter,Randomized,Controlled Phase III Clinical Study
